About

Our commitment is to improve patient safety and outcomes by redesigning laboratory diagnostic services.

Leadership

Our leadership team draws on diverse backgrounds spanning healthcare and technology.

CARy Gunn, PhD

Founder and CEO

Dr. Cary Gunn — who drives Genalyte’s strategic vision, direction, culture and success — has been blazing trails in the technology community for almost 30 years.

Prior to leading Genalyte, Cary served as co-founder and chief technical officer of Luxtera, a developer of innovative optical solutions; his military career includes almost 10 years in the United States Air Force, where he was responsible for launching GPS satellites. Holding 81 (and counting) issued U.S. patents, Cary has been recognized in publications including the MIT Technology Review, which named him a Top Young Innovator in 2003. Five years later, Cary’s achievements in silicon photonics were awarded with the Optical Society of America Adolph Lomb Medal and the Berthold-Leibinger Foundation Innovation Prize. He received his bachelor’s degree in applied physics and organic chemistry from the United States Air Force Academy and his PhD in electrical engineering from the California Institute of Technology (Caltech). At Genalyte, Cary is proud to pioneer technology that has “a positive impact on life and human health.”

Kevin Lo

President

Kevin Lo is the President of Genalyte Inc. He was previously a senior executive at Facebook leading their Connectivity efforts and before that, was co-founder and General Manager of Google Fiber.

Before joining Google, Kevin was the COO of M2Z Networks, a wireless service provider. He also served as the CFO and COO of Navisite Inc where he led the successful turnaround of the publicly traded telecom services company. Kevin founded and led two software companies, both of which were acquired in the 2000s.

A former strategy consultant at Bain & Co, Kevin got his start in software programming as a research assistant at the Jet Propulsion Laboratory. Kevin received his AB from Harvard University where he was a Harvard National Scholar.

Kevin serves on the Board of Directors for several companies including Benetech, the leading software for social good non-profit, and Nominum Inc, an enterprise software security company. He works actively on global poverty and health issues, and he’s an avid triathlete

Ted Holtaway

Chief Operating Officer

Chief Operating Officer Ted Holtaway excels in helping companies — particularly early-stage start-ups — grow and scale efficiently.

At Genalyte, he leads internal operations including supply, shipping, development and facilities. Ted’s most recent posts were senior vice president of operations at Luxtera, and vice president and managing director of Brooktree Singapore. At Cymer, he shepherded the first master oscillator power amplifier (MOPA laser) from concept to market, where it grew to hold 90 percent of global market share. Among his professional highlights, Ted was part of University of California, San Diego’s Leadership and Management Program and completed the Stanford Executive Institute executive program. Ted earned his bachelor’s degree in electrical engineering at the New Jersey Institute of Technology; his master’s in electrical engineering at the Polytechnic Institute of New York; and his master’s in business administration at San Diego State University. Ted appreciates applying his problem-solving expertise to the medical space, helping to simplify an “incredibly complex technology” into a solution that “anyone can operate in a doctor’s office.”

RICK HOCKETT, MD

CMO

A clinical pathologist certified by the American Board of Pathology, Chief Medical Officer Rick Hockett is the mind behind Genalyte’s clinical strategy, development and operations.

He also oversees daily operations of our CLIA laboratory and 510(k) submission of our proprietary diagnostic instrumentation and assays for regulatory approval. Rick has spent three decades applying biomarkers to clinical medicine, distinguishing him as a leader in personalized medicine. Among many professional achievements, Rick was responsible for the first standalone genetic component for a New Drug Application to the U.S. Food and Drug Administration. Rick maintains active medical licenses in Indiana, California, New York and Colorado. He earned his bachelor’s degree in chemistry at the University of South Dakota and his doctorate of medicine from the University of Minnesota; he completed his residency in clinical pathology at Washington University, St. Louis. He is inspired by Genalyte’s mission to empower medical practitioners and patients through tech.

Michael O’Neil

VP, Product Marketing

Michael leads Genalyte’s strategic direction by reading the market, identifying key market segments and designing innovative products and services to meet those needs.

Among his proudest career moments, O’Neil spearheaded the design and implementation of one of the first accountable care organizations in the country while serving as Senior Director of Product Innovation at Blue Shield of California. Improving quality of healthcare while cutting costs by almost $38 million in two years, the ACO model has been replicated by more than 32 medical groups and hospitals across the state. He earned his bachelor’s degree in political science from Dartmouth College and a master’s degree in education from Stanford University. With 20 years in the healthcare industry under his belt, O’Neil is inspired by Genalyte’s mission to improve patient-provider interactions with real-time data, and he’s proud to be part of bettering the lives of his friends, family and community.

SASI MUDUMBA, PHD

VP, Assay Development

Dr. Sasi Mudumba oversees the research, development, validation, regulatory submission and approval of the diagnostic assays at the heart of Genalyte’s revolutionary technology.

She has spent more than 20 years in research, development and commercialization in life sciences, drug discovery and medical devices. Mudumba has guided several In Vitro Diagnostics (IVD) products through approvals at federal agencies including the Food and Drug Administration and Health Canada, and was responsible for leading a multiplexed autoimmune IVD assay on microarray technology from development to regulatory approval. Her previous roles include Director of Assay Development at Regulatory Affairs at SQI Diagnostics and Senior Scientist at NoAb BioDiscoveries. Mudumba earned her bachelor’s degree in microbiology at Osmania University before obtaining her master’s degree in biochemistry from the Unviersity of Hyderabad; her PhD in biotechnology is from Jawaharlal Nehru Technological University. At Genalyte, she is excited to work with technology that speeds the diagnosis and treatment of autoimmune diseases.

AARON HANSON, PHD

VP Technology Transfer and Consumables Manufacturing

Aaron Hanson leads the development and transfer of Genalyte’s core technology; the production of our kits, using validated production processes; and the analysis of data and biostatistics.

With 20 years of experience in biotechnology, Hanson is responsible for ushering hundreds of millions of diagnostic devices to the global market and has expertly guided multimillion-dollar business through domestic and international expansions. Among his professional wins, Hanson is proud to hold a surface chemistry patent whose technology has been utilized in research and diagnostic applications; he is also certified through Lean and is a Six Sigma Green Belt. He earned his bachelor’s degree in biology and chemistry at Point Loma Nazarene College before achieving his PhD in pharmaceutical sciences and medicinal chemistry at the University of Nebraska Medical Center. Asked what he enjoys most about Genalyte, Hanson says he loves to “see science and technology helping people” and is passionate about helping physicians “improve lives.”

Rob Kelley

VP, Sales and Commercial Development

Rob Kelley has helped introduce the healthcare community to Genalyte’s innovative testing solutions, which change the way patients and physicians interact and shortens the waiting period from testing to diagnosis and treatment.

Prior to joining the team at Genalyte, Kelley was proud to serve at Illumina, launching the first clinically oriented, next-generation sequencing products and expanding Illumina’s global sales team. As Vice President of Marketing at Trovagene, he oversaw upstream and downstream marketing activities and lent his expertise in business development and strategic planning. Kelley has dedicated over 20 years of his career to sales for healthcare and biotechnology companies including Merck, Biosite, and Siemens Healthcare. Kelley attained his bachelor’s degree in biology at Duke University and his master’s in business administration from the University of California, Los Angeles. Kelley is driven by bringing new, cutting-edge technologies to the clinical realm, and is inspired by positively impacting the length and quality of human life.

Muzammil Iqbal

VP, Instrumentation

Muzammil Iqbal has been with the company since its inception in 2007, the first employee hired by our founders.

Overseeing Genalyte’s engineering team, Iqbal has played a key role in developing the world-class technology that is revolutionizing lab diagnostic services. Among Iqbal’s greatest accomplishments at Genalyte are his crucial contributions to the development of our Maverick Detection System™, a novel, bio-sensing platform for real-time, label-free, and multiplexed analysis of bio-molecular interactions. Prior to Genalyte, he helped advance silicon photonics technology at Luxtera and contributed to numerous patents and research articles. Iqbal holds a bachelor’s degree in electrical engineering from the NED University of Engineering and Technology as well as a PhD in electrical engineering from the University of Delaware. He enjoys contributing towards products and services that impact all tiers of healthcare.

Brittin Davis

Director, Medical Operations

Brittin oversees Genalyte’s medical operations and clinical laboratories, has established herself as an expert in forensic science at bedrock institutions including the Federal Bureau of Investigations and the Kansas Bureau of Investigations.

Davis directed the creation of the first Afghan forensic DNA laboratory following the implementation of ISO17025 regulations and acted as DNA advisor for the North Atlantic Treaty Organization’s military command. A member of the American Academy of Forensic Sciences and the American Society of Crime Laboratory Directors, Davis specializes in molecular biology, forensic applications, assay validation, quality management programs, laboratory compliance, nuclear DNA analysis, battlefield forensics and STR analysis. She carries a bachelor’s degree in forensic science from California State University, Hayward, and master’s degree in forensic science and forensic molecular biology from George Washington University. Davis loves the meaningful, challenging work at Genalyte and the opportunity to be part of a growing, evolving company.

Madonna Moreno

Director, Human Resources

A 19-year veteran of her field, Madonna Moreno can be credited with shaping Genalyte’s innovative, dynamic culture by dictating company values and people strategy.

She is responsible Genalyte’s human resources functions including talent management, employee development, benefits, compensation, and business support. A leader in her field, Moreno is president of the San Diego Life Sciences HR Network, a nonprofit organization dedicated to developing innovation and strategic human resources practices in life sciences industries. Moreno is a Certified Professional in Human Resources and a Society for Human Resources Certified Professional. Moreno holds a bachelor’s degree in political science and a master’s in business administration, both from the University of San Diego. Having spent 11 years in biotechnology and life sciences companies — including Trovagene and the Salk Institute for Biological Studies — Moreno is passionate about working with innovative thinkers, and connecting talented people with meaningful opportunities to impact health and change lives.

Craig Clark

Manager, Quality

Craig Clark has been with Genalyte since 2014, managing and implementing our quality assurance team, policies and systems.

Craig has spent more than 20 years working in Food and Drug Administration–regulated Good Manufacturing Practice environments, and his knowledge of International Organization for Standardization and FDA standards has made him a key asset in facility certifications and product approvals. Prior to joining Genaltye, Clark led quality and validation teams at Advanced BioHealing, a leading tissue-engineering company, and Shire Regenerative Medicine, a global biotech organization focused on rare diseases. His accomplishments at Genalyte include shepherding our quality assurance department through the rigorous ISO 13485:2016 certification process. Clark received his bachelor’s degree in biochemistry and cell biology from the University of California, San Diego, and his executive master’s degree in business administration from the New York Institute of Technology.

Board of Directors

Cary Gunn, Phd

Founder and CEO

Dr. Cary Gunn — who drives Genalyte’s strategic vision, direction, culture and success — has been blazing trails in the technology community for almost 30 years.

Prior to leading Genalyte, Cary served as co-founder and chief technical officer of Luxtera, a developer of innovative optical solutions; his military career includes almost 10 years in the United States Air Force, where he was responsible for launching GPS satellites. Holding 81 (and counting) issued U.S. patents, Cary has been recognized in publications including the MIT Technology Review, which named him a Top Young Innovator in 2003. Five years later, Cary’s achievements in silicon photonics were awarded with the Optical Society of America Adolph Lomb Medal and the Berthold-Leibinger Foundation Innovation Prize. He received his bachelor’s degree in applied physics and organic chemistry from the United States Air Force Academy and his PhD in electrical engineering from the California Institute of Technology (Caltech). At Genalyte, Cary is proud to pioneer technology that has “a positive impact on life and human health.”

Gerard van hamel platernik

Member, Board of Directors

Gerard joined Redmile as a managing director in May 2012.

Prior to working with Redmile, Gerard was a Managing Director with Accuitive Medical Ventures (AMV).  AMV II has recently been ranked in the top quartile of healthcare VC funds for its vintage year (Source: Cambridge Assoc.).  Gerard has cofounded a number of healthcare companies including Halscion, Sebacia and First Aid Shot Therapeutics.  In addition, Gerard led AMV’s investments in Axogen (public: AXGN), Cardiofocus, Neuronetics and Intuity Medical.  Before AMV, Gerard worked with Novoste Corporation, the cardiology technology company, in business development and corporate communications. Before joining Novoste, Gerard was an equity research analyst with Salomon Brothers (now Citigroup) in London, where he was a member of the top ranked European healthcare research team.  Gerard began his career with Kleinwort Benson, where he was an investment banker and member of the bank’s private equity and mezzanine finance group. Gerard is a Dutch national, was born in Borneo in Southeast Asia, grew up in Africa and was educated in the UK where he got his BS in Physics (1st Class Honors) from St. Andrews University and an MBA from Cambridge University.

VIJIT SABNIS

Member, Board of Directors

Vijit is a venture partner at Khosla Ventures, where he focuses on emerging physical and life science technologies spanning a broad range of sectors including consumer, health, energy, sustainability, computation and communications.

Prior to Khosla Ventures, Vijit was a co-founder and the CEO of Solar Junction, a manufacturer of high-efficiency multi-junction solar cells, where he helped solve a long-standing materials science challenge and subsequently achieved two world records in solar cell efficiency. The company was later acquired by Taqnia International, the U.S. subsidiary of the Saudi Technology Development and Investment Company.

Previously, Vijit was an early employee at Translucent, a startup developing advanced semiconductor technologies for the electronics and photonics markets. While there, he focused on developing complementary metal-oxide semiconductor (CMOS) chip-compatible lasers that would enable inter- and intra-chip and rack optical communications without the speed and power limitations associated with traditional copper electrical interconnect. He also led the team to create the world’s first rare-earth oxide light emitters for integration into silicon waveguides and win a multi-year contract from the Defense Advanced Research Projects Agency (DARPA) contract. Translucent was acquired by Silex Systems [ASX: SLX].

While he was a graduate student at Stanford, Vijit helped incubate a new laser technology that led to the formation of the Santur Corporation. The company developed the laser technology into the number one tunable laser product in the world and was acquired by Neophotonics [NYSE: NPTN].

Vijit holds a bachelor’s of science degree in electrical engineering and computer science with highest honors from the University of California, Berkeley. He also holds a master’s of science degree and doctor of philosophy degree in electrical engineering from Stanford University, where he received a National Science Foundation fellowship and a Stanford electrical engineering department fellowship. His dissertation focused on developing and demonstrating optically controlled electro-absorption modulators as efficient wavelength converters for integration into optical routers.

In his spare time, Vijit enjoys the outdoors including but not limited to hiking, running and tennis. As an enthusiastic sports fan, he closely follows the Los Angeles Lakers, the San Francisco 49ers and Giants, in addition to his both his alma maters’ sports teams.

William A. Hagstrom

Member, Board of Directors

William A. Hagstrom is the founder and CEO of Octave Bioscience and the former CEO of Crescendo Bioscience

Mr. Hagstrom brings more than three decades of executive and board-level experience in the healthcare and diagnostic sectors to Genalyte. He is currently the founder and CEO of Octave Bioscience, an early-stage diagnostics company focused on neurodegenerative diseases.

At Crescendo, which focused on diagnostics related to autoimmune and inflammatory diseases, Mr. Hagstrom secured financing and led the development of the company’s commercial strategy and product pipeline before it was acquired by Myriad Genetics in 2014.

Prior to joining Crescendo, Mr. Hagstrom served as president of Alpha BioPartners, a strategic consulting firm specializing in early-stage biotechnology companies. While there, he co-founded Biolytx Pharmaceuticals and Altheus Therapeutics, and served as interim CEO of Selexys Pharmaceuticals and Inoveon. Mr. Hagstrom also served as the Chairman and CEO of specialty diagnostics firm UroCor, as well as held executive positions at multinational healthcare firms Becton Dickinson, American Hospital Supply and Baxter International.

Mr. Hagstrom holds B.S. in Business Management from Bob Jones University.

Investors

A blog about Wordpress design, development , Software and inspiration http://themesharebd.blogspot.com